戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 COPD," and 1,590 (38.8%) as "unaffected" (no obstructive airway disease).
2  to the later development or exacerbation of obstructive airway disease.
3 induced bronchoconstriction in patients with obstructive airway disease.
4  in mortality and morbidity in patients with obstructive airway disease.
5 y improved oxygenation only in patients with obstructive airway disease.
6 tially important therapeutic implications in obstructive airway diseases.
7 otentially important therapeutic targets for obstructive airway diseases.
8 ae seropositivity and both acute and chronic obstructive airway diseases.
9 hat is up-regulated in patients with chronic obstructive airways disease.
10  [12%] deaths), mainly pneumonia and chronic obstructive airways disease.
11 as well as non-CF bronchiectasis and chronic obstructive airways disease.
12 le asthma," 1,996 (31.1%) as "unclassifiable obstructive airway disease," 228 (3.5%) as "COPD," and 2
13 d 42.8% of the facial mask group) or chronic obstructive airway disease (34.3% of the nasal mask grou
14 le asthma," 1,193 (29.1%) as "unclassifiable obstructive airway disease, " 626 (15.3%) as "COPD," and
15 /2 years) and in 15 control patients without obstructive airway disease (age range, 2 months to 7 yea
16 ceptor agonists are used in the treatment of obstructive airway disease and overactive bladder syndro
17 c syndrome-related conditions, inhalants for obstructive airway diseases and glucocorticoid use.
18  phenotyping can help in understanding these obstructive airway diseases and provide guidance for dis
19 cardiopulmonary conditions, including severe obstructive airways disease and left ventricular dysfunc
20 he 6 diagnoses (congestive heart failure and obstructive airways disease) and similar for the other 4
21 hanges recapitulate aspects of complex human obstructive airway diseases, but their molecular mechani
22 matics (A; n = 5), and patients with chronic obstructive airway disease (COPD; n = 10).
23                       Weight loss in chronic obstructive airways disease (COPD) is associated with an
24 eover, they stipulated that the phenotype of obstructive airway disease could be affected by sex and
25 se, spontaneous pneumothorax associated with obstructive airway disease from chronic GVHD after bone
26 s' call to carefully phenotype patients with obstructive airways diseases has been adopted by many cu
27 ng function and an increased risk of chronic obstructive airway disease in adulthood.
28 for sudden fetal and infant death as well as obstructive airway disease in childhood.
29 ndings give unique insight into the cause of obstructive airways disease in 18-year-olds, and follow-
30 portunity to describe the latency period for obstructive airway disease (OAD) diagnoses.
31 n the allograft rejection that characterizes obstructive airway disease (OAD).
32              Neither the association between obstructive airways disease (OAD) and sleep apnea-hypopn
33                         Use of inhalants for obstructive airway diseases (PR = 0.79; 95% CI = 0.74-0.
34 chanisms that exaggerate mucin production in obstructive airway diseases remain unknown.
35 rt disease, cerebrovascular disease, chronic obstructive airways disease, sex, or treatment method.
36 us hypersecretion is an important feature of obstructive airway diseases such as asthma, chronic obst
37 d natural history of imminent pediatric muco-obstructive airway diseases such as cystic fibrosis rema
38  upregulated in the airways of subjects with obstructive airway diseases, to its unique GPCR CCR6 ind
39      Subsequent mortality and medication for obstructive airway disease were ascertained at 5-yr foll
40 and provisional diagnoses of restrictive and obstructive airway disease were assigned based on percen

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。